EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), today announced positive interim data from the ongoing pegloticase open label extension (OLE) to the Phase 3 pivotal trials in patients with treatment-failure gout. The interim results are based on the OLE data cut at the end of September 2007.
